EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship

Experimental Dermatology

Volumn 23, Issue 1, 2014, Pages 33-38

  Sayar, Beyza S ^a   Rüegg, Simon ^a   Schmidt, Enno ^b   Sibilia, Maria ^c   Siffert, Myriam ^a   Suter, Maja M ^a   Galichet, Arnaud ^a   Müller, Eliane J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF LÜBECK   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

C Myc; EGFR; EGFR inhibitors; Erlotinib; Lapatinib; P38MAK; Pemphigus vulgaris signalling; Pilot study

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; LAPATINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLISTER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; MOUSE; NEWBORN; NONHUMAN; ORAL BLISTER; PEMPHIGUS VULGARIS; PROTEIN FUNCTION; REFERENCE VALUE; SIGNAL TRANSDUCTION;

C-MYC; EGFR; EGFR INHIBITORS; ERLOTINIB; LAPATINIB; P38MAK; PEMPHIGUS VULGARIS SIGNALLING; PILOT STUDY;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; DESMOGLEIN 1; DESMOGLEIN 3; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KERATINOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NONLINEAR DYNAMICS; PEMPHIGUS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84891363710     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12290     Document Type: Article

References (32)

1. Ishii K, Amagai M, Hall R P et al. J. Immunol. 1997: 159: 2010-2017.
2. Ding X, Aoki V, Mascaro J M et al. J Invest Dermatol 1997: 109: 592-596.
3. Getsios S, Waschke J, Borradori L et al. J Invest Dermatol 2010: 130: 1764-1768.
4. Müller E J, Williamson L, Kolly C et al. J Invest Dermatol 2008: 128: 501-516.
5. Kasperkiewicz M, Schmidt E. Curr Drug Discov Technol 2009: 6: 270-280.
6. Williamson L, Raess N A, Caldelari R et al. EMBO J 2006: 25: 3298-3309.
7. Pretel M, Espana A, Marquina M et al. Exp Dermatol 2009: 18: 771-780.
8. Berkowitz P, Hu P, Warren S et al. PNAS 2006: 103: 12855-12860.
9. Espana A, Modol T, Gil M P et al. Exp Dermatol 2013: 22: 125-130.
10. Gil M P, Modol T, Espana A et al. Exp Dermatol 2012: 21: 254-259.
11. Mao X, Sano Y, Park J M et al. J Biol Chem 2011: 286: 1283-1291.
12. Rubenstein D S, Werth V, Strober B et al. http://clinicaltrials.gov/ 2008.
13. Heupel W M, Engerer P, Schmidt E et al. Am J Pathol 2009: 174: 475-485.
14. Mahoney M G, Wang Z, Rothenberger K et al. J Clin Invest 1999: 103: 461-468.
15. Schulze K, Galichet A, Sayar B S et al. J Invest Dermatol 2012: 132: 346-355.
16. Tsunoda K, Ota T, Aoki M et al. J Immunol 2003: 170: 2170-2178.
17. Agero A L C, Dusza S W, Benvenuto-Andrade C et al. J Am Acad Dermatol 2006: 55: 657-670.
18. Oteri A, Cattaneo M T, Filipazzi V et al. Oncologist 2009: 14: 1201-1204.
19. Lichtenberger B M, Tan P K, Niederleithner H et al. Cell 2010: 140: 268-279.
20. de Bruin A, Caldelari R, Williamson L et al. Exp Dermatol 2007: 16: 468-475.
21. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2013. Available at: http://www.R-project.org/.
22. Muggeo V M. Stat Med 2003: 22: 3055-3071.
23. Muggeo V M. segmented: an R Package to Fit Regression Models with broken-line relationships. R News, 8/1, 20-25, 2008. Available at: http://cran.r-project.org/doc/Rnews/.
24. Frusic-Zlotkin M, Raichenberg D, Wang X et al. Autoimmunity 2006: 39: 563-575.
25. Chernyavsky A I, Arredondo J, Kitajima Y et al. J Biol Chem 2007: 282: 13804-13812.
26. Moy B, Goss P E. Oncologist 2007: 12: 756-765.
27. Moyer J D, Barbacci E G, Iwata K K et al. Cancer Res 1997: 57: 4838-4848.
28. Medina P J, Goodin S. Clin Ther 2008: 30: 1426-1447.
29. Lichtenberger B M, Gerber P A, Holcmann M et al. Sci Transl Med 2013: 5: 199ra111.
30. Calautti E, Li J, Saoncella S et al. J Biol Chem 2005: 280: 32856-32865.
31. Butz S, Stappert J, Weissig H et al. Science 1992: 257: 1142-1144.
32. Tsang S M, Liu L, Teh M T et al. PLoS ONE 2010: 5: e14211.